Menu

Pipeline Overview

Drug Planned
Indication
Pre-clinical Phase i/ii Phase iii NDA/MAA Filing
GI & Inflammation
RHB-105 H. pylori infections
RHB-104 Crohn's disease
Multiple sclerosis
RHB-106 Bowel cleanser
BEKINDA™
(RHB-102)
Gastroenteritis & gastritis
Oncology - GI/Inflammation
Oncology support
ABC294640 Multiple indications
MESUPRON® Solid tumors
RP101 Pancreatic cancer
Other
RIZAPORT™
(RHB-103)
Migraine
*Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies; Timeline presented in this pipeline may apply to different regulatory paths (U.S, EU, etc.)

Company Profile

RedHill Biopharma (NASDAQ / TASE: RDHL) is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary, orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers.

Read more